Tejara Capital Ltd Decreases Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Tejara Capital Ltd decreased its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 36.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 153,739 shares of the company’s stock after selling 87,874 shares during the period. Tejara Capital Ltd owned 0.20% of Trevi Therapeutics worth $633,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of TRVI. BNP Paribas Financial Markets increased its stake in shares of Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after purchasing an additional 6,764 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Trevi Therapeutics in the fourth quarter worth about $49,000. Intech Investment Management LLC purchased a new position in shares of Trevi Therapeutics in the third quarter worth about $63,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Trevi Therapeutics in the fourth quarter worth about $67,000. Finally, SG Americas Securities LLC increased its stake in shares of Trevi Therapeutics by 14.5% in the fourth quarter. SG Americas Securities LLC now owns 26,792 shares of the company’s stock worth $110,000 after purchasing an additional 3,387 shares in the last quarter. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on TRVI shares. D. Boral Capital reiterated a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research note on Friday, March 7th. Oppenheimer raised their price objective on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. HC Wainwright raised their price objective on shares of Trevi Therapeutics from $7.50 to $12.50 and gave the company a “buy” rating in a research report on Monday, March 10th. Raymond James upgraded shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $9.00 to $29.00 in a research report on Monday, March 10th. Finally, Needham & Company LLC raised their price objective on shares of Trevi Therapeutics from $8.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Seven investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $15.94.

Trevi Therapeutics Price Performance

Shares of Trevi Therapeutics stock opened at $6.54 on Tuesday. Trevi Therapeutics, Inc. has a 1 year low of $2.30 and a 1 year high of $7.39. The firm has a market cap of $502.70 million, a PE ratio of -14.86 and a beta of 0.90. The company has a 50 day simple moving average of $4.39 and a two-hundred day simple moving average of $3.66.

Insider Buying and Selling at Trevi Therapeutics

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the sale, the insider now directly owns 76,900 shares in the company, valued at $519,075. The trade was a 51.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 24.37% of the stock is currently owned by company insiders.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.